These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Tsochatzis EA; Papatheodoridis GV; Archimandritis AJ Mediators Inflamm; 2009; 2009():831670. PubMed ID: 19753129 [TBL] [Abstract][Full Text] [Related]
8. [Clinical utility of angiotensin II receptor antagonist]. Yokohama S; Nakamura K; Haneda M Nihon Rinsho; 2006 Jun; 64(6):1152-6. PubMed ID: 16768124 [TBL] [Abstract][Full Text] [Related]
9. [Diabetes and the metabolic syndrome]. Yamauchi T; Kadowaki T Nihon Yakurigaku Zasshi; 2006 Sep; 128(3):133-40. PubMed ID: 16971775 [No Abstract] [Full Text] [Related]
10. Emerging drugs for non-alcoholic steatohepatitis. Tomeno W; Yoneda M; Imajo K; Ogawa Y; Kessoku T; Saito S; Eguchi Y; Nakajima A Expert Opin Emerg Drugs; 2013 Sep; 18(3):279-90. PubMed ID: 23848366 [TBL] [Abstract][Full Text] [Related]
11. Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effects. Kurita S; Takamura T; Ota T; Matsuzawa-Nagata N; Kita Y; Uno M; Nabemoto S; Ishikura K; Misu H; Ando H; Zen Y; Nakanuma Y; Kaneko S Eur J Pharmacol; 2008 Jul; 588(2-3):316-24. PubMed ID: 18501344 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob/ob male mice. Kato J; Koda M; Kishina M; Tokunaga S; Matono T; Sugihara T; Ueki M; Murawaki Y Int J Mol Med; 2012 Jul; 30(1):107-13. PubMed ID: 22469867 [TBL] [Abstract][Full Text] [Related]
13. [Pathophysiology of NASH]. Takei Y; Ikejima K; Sato N Nihon Shokakibyo Gakkai Zasshi; 2004 Nov; 101(11):1194-203. PubMed ID: 15570867 [No Abstract] [Full Text] [Related]